Raleigh, North Carolina, United States, July 2025 – Sarah Krepp has taken on a new role as Chief Human Resources Officer at Liquidia Corporation, further strengthening the company’s leadership team as it continues to expand its innovative pipeline in pulmonary hypertension. In this elevated role, Sarah will lead Liquidia’s people strategy, organizational development, and culture transformation efforts, driving employee engagement and operational excellence across the organization.
Sarah has been with Liquidia Corporation for over two years, serving initially as Vice President, People and Culture, and then advancing to Senior Vice President, People and Culture before stepping into her current role. During her tenure, she has been instrumental in building a high-performance culture, aligning HR operations with strategic business goals, and enhancing leadership development and talent programs across the company.
Before joining Liquidia, Sarah served as Head of People and Culture at FUJIFILM Diosynth Biotechnologies, where she led strategic HR initiatives and partnered with executive leadership to shape people practices for a rapidly growing biopharmaceutical organization. Her tenure at FUJIFILM further solidified her reputation as a trusted advisor and transformational HR leader.
She also held key leadership roles at Istari Oncology, where she was SVP of Human Resources and Administration, and earlier as Vice President of Human Resources. During this time, she led organizational design, talent acquisition, and change management initiatives critical to scaling the company’s biotech operations.
Her HR journey also includes a five-year tenure at Chimerix, Inc., where she served as Associate Director, Human Resources, and previous HR roles at Salix Pharmaceuticals and PRA Health Sciences, where she specialized in recruitment, coaching, and HR operations.
About Liquidia Corporation
Liquidia Corporation is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other diseases through its proprietary PRINT® Technology. The company’s lead product candidate, YUTREPIA™ (treprostinil) inhalation powder, is in development for the treatment of PAH and PH-ILD. Liquidia also operates Liquidia PAH, a subsidiary responsible for the commercialization of treatments for pulmonary diseases, including generic Treprostinil Injection. Headquartered in Raleigh, North Carolina, Liquidia is committed to improving the lives of patients through innovation and precision drug delivery.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
